Author:
Mooi J.K.,Wirapati P.,Asher R.,Lee C.K.,Savas P.,Price T.J.,Townsend A.,Hardingham J.,Buchanan D.,Williams D.,Tejpar S.,Mariadason J.M.,Tebbutt N.C.
Funder
National Health and Medical Research Council
NHMRC
Ludwig Cancer Research; the Operational Infrastructure Support Program
Victorian Government
NHMRC Senior Research Fellowship
JMM
BEAT Cancer Council South Australia
Perpetual Philanthropic Grants
Almac Diagnostics, Craigavon
Reference17 articles.
1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
2. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008
3. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study;Tebbutt;J Clin Oncol,2010
4. The consensus molecular subtypes of colorectal cancer;Guinney;Nat Med,2015
5. Almac Xcel Array for FFPE Profiling (Datasheet). Almac, Craigavon, UK. https://www.almacgroup.com/wp-content/uploads/2017/05/almac_xcel_array_datasheet.pdf (26 September 2018, date last accessed).
Cited by
112 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献